Denmark · Delayed Price · Currency is DKK ChemoMetec Statistics
Total Valuation
ChemoMetec has a market cap or net worth of DKK 9.43 billion. The enterprise value is 9.18 billion.
| Market Cap | 9.43B |
| Enterprise Value | 9.18B |
Important Dates
The next estimated earnings date is Thursday, September 11, 2025.
| Earnings Date | Sep 11, 2025 |
| Ex-Dividend Date | Oct 11, 2024 |
Share Statistics
ChemoMetec has 17.40 million shares outstanding. The number of shares has decreased by -0.13% in one year.
| Current Share Class | 17.40M |
| Shares Outstanding | 17.40M |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 45.20% |
| Float | 17.34M |
Valuation Ratios
The trailing PE ratio is 55.76 and the forward PE ratio is 43.79. ChemoMetec's PEG ratio is 4.09.
| PE Ratio | 55.76 |
| Forward PE | 43.79 |
| PS Ratio | 20.53 |
| PB Ratio | 15.77 |
| P/TBV Ratio | 20.29 |
| P/FCF Ratio | 61.98 |
| P/OCF Ratio | 53.53 |
| PEG Ratio | 4.09 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 41.71, with an EV/FCF ratio of 60.30.
| EV / Earnings | 54.27 |
| EV / Sales | 19.97 |
| EV / EBITDA | 41.71 |
| EV / EBIT | 43.62 |
| EV / FCF | 60.30 |
Financial Position
The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.00 |
| Quick Ratio | 2.88 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 30.83% and return on invested capital (ROIC) is 23.68%.
| Return on Equity (ROE) | 30.83% |
| Return on Assets (ROA) | 19.86% |
| Return on Invested Capital (ROIC) | 23.68% |
| Return on Capital Employed (ROCE) | 34.62% |
| Revenue Per Employee | 2.50M |
| Profits Per Employee | 918,918 |
| Employee Count | 174 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 0.33 |
Taxes
In the past 12 months, ChemoMetec has paid 51.32 million in taxes.
| Income Tax | 51.32M |
| Effective Tax Rate | 23.29% |
Stock Price Statistics
The stock price has increased by +47.68% in the last 52 weeks. The beta is 1.53, so ChemoMetec's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | +47.68% |
| 50-Day Moving Average | 521.55 |
| 200-Day Moving Average | 514.36 |
| Relative Strength Index (RSI) | 63.36 |
| Average Volume (20 Days) | 24,992 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ChemoMetec had revenue of DKK 459.54 million and earned 169.08 million in profits. Earnings per share was 9.72.
| Revenue | 459.54M |
| Gross Profit | 418.51M |
| Operating Income | 210.34M |
| Pretax Income | 220.40M |
| Net Income | 169.08M |
| EBITDA | 219.98M |
| EBIT | 210.34M |
| Earnings Per Share (EPS) | 9.72 |
Balance Sheet
The company has 264.74 million in cash and 7.78 million in debt, giving a net cash position of 256.96 million or 14.77 per share.
| Cash & Cash Equivalents | 264.74M |
| Total Debt | 7.78M |
| Net Cash | 256.96M |
| Net Cash Per Share | 14.77 |
| Equity (Book Value) | 597.98M |
| Book Value Per Share | 34.36 |
| Working Capital | 368.22M |
Cash Flow
In the last 12 months, operating cash flow was 176.20 million and capital expenditures -24.04 million, giving a free cash flow of 152.17 million.
| Operating Cash Flow | 176.20M |
| Capital Expenditures | -24.04M |
| Free Cash Flow | 152.17M |
| FCF Per Share | 8.74 |
Margins
Gross margin is 91.07%, with operating and profit margins of 45.77% and 36.79%.
| Gross Margin | 91.07% |
| Operating Margin | 45.77% |
| Pretax Margin | 47.96% |
| Profit Margin | 36.79% |
| EBITDA Margin | 47.87% |
| EBIT Margin | 45.77% |
| FCF Margin | 33.11% |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 0.74%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 0.74% |
| Dividend Growth (YoY) | -33.33% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 41.15% |
| Buyback Yield | 0.13% |
| Shareholder Yield | 0.89% |
| Earnings Yield | 1.79% |
| FCF Yield | 1.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ChemoMetec has an Altman Z-Score of 34.57 and a Piotroski F-Score of 4.
| Altman Z-Score | 34.57 |
| Piotroski F-Score | 4 |